The findings from the NORDynamIC study, enrolling 382 HCV genotype 2- or 3-infected patients treated with standard 800-mg dosing of ribavirin in combination with interferon, demonstrated that patients carrying ITPA variants encoding reduced ITPase activity showed increased treatment efficacy mediated by reduced relapse risk and less anemia (2). Here, ITPA is linked to anemia (phenotype).